Literature DB >> 35395398

Neuronal genetic rescue normalizes brain network dynamics in a lysosomal storage disorder despite persistent storage accumulation.

Rebecca C Ahrens-Nicklas1, Luis Tecedor2, Arron F Hall3, Owen Kane3, Richard J Chung3, Elena Lysenko2, Eric D Marsh4, Colleen S Stein5, Beverly L Davidson6.   

Abstract

Although neurologic symptoms occur in two-thirds of lysosomal storage disorders (LSDs), for most we do not understand the mechanisms underlying brain dysfunction. A major unanswered question is if the pathogenic hallmark of LSDs, storage accumulation, induces functional defects directly or is a disease bystander. Also, for most LSDs we do not know the impact of loss of function in individual cell types. Understanding these critical questions are essential to therapy development. Here, we determine the impact of genetic rescue in distinct cell types on neural circuit dysfunction in CLN3 disease, the most common pediatric dementia and a paradigmatic neurodegenerative LSD. We restored Cln3 expression via AAV-mediated gene delivery and conditional genetic rescue in a CLN3 disease mouse model. Surprisingly, we found that low-level rescue of Cln3 expression in neurons alone normalized clinically relevant electrophysiologic markers of network dysfunction, despite the presence of substantial residual histopathology, in contrast to restoring expression in astrocytes. Thus, loss of CLN3 function in neurons, not storage accumulation, underlies neurologic dysfunction in CLN3 disease. This impliesies that storage clearance may be an inappropriate target for therapy development and an ineffectual biomarker.
Copyright © 2022 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CLN3 disease; gene therapy; lysosomal storage disease; neuronal dysfunction

Mesh:

Substances:

Year:  2022        PMID: 35395398      PMCID: PMC9263320          DOI: 10.1016/j.ymthe.2022.03.025

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  43 in total

1.  Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis.

Authors:  Caroline Gregorian; Jonathan Nakashima; Janel Le Belle; John Ohab; Rachel Kim; Annie Liu; Kate Barzan Smith; Matthias Groszer; A Denise Garcia; Michael V Sofroniew; S Thomas Carmichael; Harley I Kornblum; Xin Liu; Hong Wu
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

2.  Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates.

Authors:  Lluis Samaranch; Ernesto A Salegio; Waldy San Sebastian; Adrian P Kells; Kevin D Foust; John R Bringas; Clementine Lamarre; John Forsayeth; Brian K Kaspar; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-03-28       Impact factor: 5.695

3.  Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.

Authors:  Steven J Gray; Valerie Matagne; Lavanya Bachaboina; Swati Yadav; Sergio R Ojeda; R Jude Samulski
Journal:  Mol Ther       Date:  2011-04-12       Impact factor: 11.454

4.  Gene Therapy Targeting the Inner Retina Rescues the Retinal Phenotype in a Mouse Model of CLN3 Batten Disease.

Authors:  Sophia-Martha Kleine Holthaus; Mikel Aristorena; Ryea Maswood; Olha Semenyuk; Justin Hoke; Aura Hare; Alexander J Smith; Sara E Mole; Robin R Ali
Journal:  Hum Gene Ther       Date:  2020-07       Impact factor: 5.695

5.  Exogenous Galactosylceramide as Potential Treatment for CLN3 Disease.

Authors:  Sally El-Sitt; Jihane Soueid; Katia Maalouf; Nadine Makhoul; Jamal Al Ali; Joelle Makoukji; Bilal Asser; Daniel Daou; Hayat Harati; Rose-Mary Boustany
Journal:  Ann Neurol       Date:  2019-08-28       Impact factor: 10.422

6.  A knock-in reporter model of Batten disease.

Authors:  Steven L Eliason; Colleen S Stein; Qinwen Mao; Luis Tecedor; Song-Lin Ding; D Meredith Gaines; Beverly L Davidson
Journal:  J Neurosci       Date:  2007-09-12       Impact factor: 6.167

7.  Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation.

Authors:  Charlie C Pontikis; Claire V Cella; Nisha Parihar; Ming J Lim; Shubhodeep Chakrabarti; Hannah M Mitchison; William C Mobley; Payam Rezaie; David A Pearce; Jonathan D Cooper
Journal:  Brain Res       Date:  2004-10-15       Impact factor: 3.252

Review 8.  Selectivity and types of cell death in the neuronal ceroid lipofuscinoses.

Authors:  Hannah M Mitchison; Ming J Lim; Jonathan D Cooper
Journal:  Brain Pathol       Date:  2004-01       Impact factor: 6.508

9.  A taxonomy of transcriptomic cell types across the isocortex and hippocampal formation.

Authors:  Zizhen Yao; Cindy T J van Velthoven; Thuc Nghi Nguyen; Jeff Goldy; Adriana E Sedeno-Cortes; Fahimeh Baftizadeh; Darren Bertagnolli; Tamara Casper; Megan Chiang; Kirsten Crichton; Song-Lin Ding; Olivia Fong; Emma Garren; Alexandra Glandon; Nathan W Gouwens; James Gray; Lucas T Graybuck; Michael J Hawrylycz; Daniel Hirschstein; Matthew Kroll; Kanan Lathia; Changkyu Lee; Boaz Levi; Delissa McMillen; Stephanie Mok; Thanh Pham; Qingzhong Ren; Christine Rimorin; Nadiya Shapovalova; Josef Sulc; Susan M Sunkin; Michael Tieu; Amy Torkelson; Herman Tung; Katelyn Ward; Nick Dee; Kimberly A Smith; Bosiljka Tasic; Hongkui Zeng
Journal:  Cell       Date:  2021-05-17       Impact factor: 66.850

10.  Exogenous Flupirtine as Potential Treatment for CLN3 Disease.

Authors:  Katia Maalouf; Joelle Makoukji; Sara Saab; Nadine J Makhoul; Angelica V Carmona; Nihar Kinarivala; Noël Ghanem; Paul C Trippier; Rose-Mary Boustany
Journal:  Cells       Date:  2020-08-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.